Thioridazine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Fenton, M ^b   Rathbone, J ^b   Reilly, Joe ^a   Sultana, A ^b  

^a DURHAM UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Antipsychotic agents adverse effects; *therapeutic use ; Arrhythmias, cardiac chemically induced ; Outcome assessment (health care); Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ATROPINE; CHLORAL HYDRATE; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOTIAPINE; CLOZAPINE; FLUPHENAZINE; GAMMA ENDORPHIN[DEENKEPHALIN]; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NITRAZEPAM; PERICIAZINE; PHENOBARBITAL; PIMOZIDE; PIPERACETAZINE; PLACEBO; REMOXIPRIDE; RESERPINE; SULPIRIDE; THIORIDAZINE; TIOSPIRONE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ABNORMAL LABORATORY RESULT; AKATHISIA; AKINESIA; ATAXIA; BLURRED VISION; BREAST SWELLING; CLINICAL TRIAL; COCHRANE LIBRARY; CONCENTRATION LOSS; CONFIDENCE INTERVAL; CONFUSION; CONSTIPATION; DATA EXTRACTION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; DYSTONIA; ECG ABNORMALITY; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FEVER; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INFECTION; INSOMNIA; LACTATION; LENS DEPOSIT; LENS DISEASE; LIVER DISEASE; MEDICAL LITERATURE; MEDLINE; MEMORY DISORDER; MICTURITION DISORDER; MOTOR DYSFUNCTION; NAUSEA; NOSE CONGESTION; OCULOGYRIC CRISIS; OUTCOME ASSESSMENT; PARKINSONISM; PHOTOSENSITIVITY; PUBLICATION; RASH; RETINA PIGMENT DEGENERATION; REVIEW; RIGIDITY; SALIVATION; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SWEATING; SWELLING; SYNCOPE; TACHYCARDIA; THORAX PAIN; TORSADE DES POINTES; TREATMENT OUTCOME; TREMOR; URINARY DYSFUNCTION; URINE RETENTION; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 42149149945     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001944.pub2     Document Type: Review

References (180)

1. Barker 1969a {published data only} Barker JC, Miller M. A double blind comparative trial of pericyazine and thioridazine in chronic schizophrenia. British Journal of Psychiatry 1969;115(519):169-72.
2. Bergling 1975 {published data only} *Bergling R, Mjorndal T, Oreland L, Rapp W, Wold S. Plasma levels and clinical effects of thioridazine and thiothixene. Journal of Clinical Pharmacology 1975;15(2-3):178-86.
3. Borison 1989 {published data only} *Borison RL, Sinha D, Haverstock S, McLarnon MC, Diamond BI. Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial. Psychopharmacology Bulletin 1989;5(2):190-3.
4. Carranza 1974 {published data only} Carranza Acevedo J, Angel Toro L, Gomez-Mont F. Double blind evaluation of sulpiride and thioridazine in paranoid schizophrenia. 9th Congres de Neuropsychopharmacologie. Nouveaux Developements du Sulpiride; 1974 Jul 10, Paris. 1974.
5. Chen 1995 {published data only} *Chen J, Zhao J, Chen Y. A randomized control study of thioridazine and chlorpromazine on treatment of schizophrenia. Chinese Journal of Neurology and Psychiatry 1995;28:329-32.
6. Clark 1971 {published data only} Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. Archives of General Psychiatry 1971;25(5):404-9.
7. Clark 1975 {published data only} Clark ML, Huber WK, Hill D, Wood F, Costiloe JP. Pimozide in chronic Schizophrenic outpatients. Diseases of the Nervous System 1975;36:137-41.
8. Cohler 1966 {published data only} Cohler J, Grinspoon L, Shader R, Chatterjee S. Behavioral correlates of the guessing game. Side effects and double-blind studies. Archives of General Psychiatry 1966;15(3):279-87.
9. Dufresne 1993 {published data only} Dufresne RL, Valentino D, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin 1993;29(2):249-55.
10. Evans 1972 {published data only} Evans JR, Rodnick EH, Goldstein MJ, Judd LL. Premorbid adjustment, phenothiazine treatment, and remission in acute schizophrenics. Archives of General Psychiatry 1972;27(4):486-90.
11. Galbrecht 1968 {published data only} Galbrecht CR, Klett CJ. Predicting response to phenothiazines: the right drug for the right patient. Journal of Nervous and Mental Disease 1968;147:173-83.
12. Gallant 1972 {published data only} Gallant. Piperacetazine vs. thioridazine-1. Early Clinical Drug Evaluation Unit Reports 1971. [MEDLINE: 97344288].
13. Gallant DM, Bishop MP. Quide vs. Mellaril in chronic schizophrenic patients. Current Therapeutic Research January 1972;14(1):10-6.
14. Gardos 1978 {published data only} Gardos G, Tecce J, Harteman E, Bowers P, Cole J. Treatment with mesoridazine and thioridazine in chronic schizophrenia. I. Assessment of clinical and electrophysiologic responses in refractory hallucinating schizophrenics. Comprehensive Psychiatry 1978;19(6):517-25.
15. Granacher 1982 {published data only} Granacher RP, Douglas R. A comparison of thioridazine (mellaril) and thiothixene (navane) in the treatment of hospitalized psychotic patients. Current Therapeutic Research 1982;31:692-705.
16. Grinspoon 1967 {published data only} Grinspoon L, Ewalt JR, Shader R. Long-term treatment of chronic schizophrenia. A preliminary report. International Journal of Psychiatry 1967;4(2):116-28.
17. Gui-Yun 1988 {published data only} Gui-yun G, Guoging Z. A double blind controlled study for the efficacy and the side effects of thioridazine and chlorpromazine in schizophrenia. Chinese Journal of Neurology and Psychiatry 1988;21(5):300-2.
18. Herrera 1990 {published data only} Herrera John, Costa J, Sramek John, Heh C. The efficacy of sustained release thioridazine in the treatment of schizophrenic inpatients. Current Therapeutic Research 1990;48:1006-11.
19. Ju 1997 {published data only} Ju FenYing, Zhu DongSheng, Liu Yan Lu Wei hong, Wang XiuHua, Jiao YuMei, Wang WenZhong, Zhu WeiMing. The randomised control trial of thioridazine and sulpiride treating schizophrenia with negative symptoms. Sichuan Mental Health 1997;10(3):171-72.
20. Judah 1958 {published data only} Judah L, Murphree O, Seager L. Psychiatric response of geriatric-psychiatric patients to Mellaril (TP-21 Sandoz). American Journal of Psychiatry 1959;115:1118-9.
21. Keks 1994 {published data only} Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, Varghese F, George T, Hustig H, Burnett P, Kerr K, Zorbas A, Hill C, Steadman T, Johnson G, Lerbert B, Copolov D, Mackenzie M, Dillenbeck C. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatrica Scandinavica 1994;90(5):358-65.
22. Lambert T, Keks N, McGrath J, Catts S, Hustig H, Vaddadi K, Burrows G, Varghese F, George T, Kerr K, Johnson G, Burnett P, Zorbas A, Hill. Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug-naive patients - A case for specific, low potency D2 antagonists. Human Psychopharmacology 1995;10(6):455-60.
23. Kramer 1978 {published data only} Kramer M, Roth T, Salis PJ. Relative efficacy and safety of loxapine succinate (Loxitane(R)) and thioridazine hydrochloride (Mellaril(R)) in the treatment of acute schizophrenia. Current Therapeutic Research 1978;23(5, Pt 2):619-31.
24. Lasky 1961 {published data only} Lasky JJ, Klett CJ, Caffey EM, Bennett JL, Rosenblum MP, Hollister LE. Drug treatment of schizophrenic patients. A comparative evaluation of chlorpromazine, chloprothixene, fluphenazine, reserpine, thioridazine and triflupromazine. Diseases of the Nervous System 1962;23:698-706.
25. Liu 1994 {published data only} Liu BingLang, Chen YY, Yang DS. Effects of thioridazine on schizophrenics and clinical utility of plasma levels. Chinese Journal of Neurology and Psychiatry 1994;27:364-7.
26. Liu BingLun, Cheng YangGuang, Yang DeSen, YangLing, Zuo ChengYe. Thioridazine in the treatment of schizophrenia: a double-blind controlled clinical trial compared with clozapine. Shanghai Archives of Psychiatry 1995;7(4):253-55.
27. McCreadie 1988 {published data only} McCreadie RG, Todd N, Livingston M, Eccleston D, Watt JA, Herrington RN, Tait D, Crocket G, Mitchell MJ, Huitfeldt B. A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatrica Scandinavica Supplementum 1990;358:136-7.
28. McCreadie RG, Todd N, Livingston M, Eccleston D, Watt JA, Tait D, Crocket G, Mitchell MJ, Huitfeldt B. A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatrica Scandinavica 1988;78(1):49-56.
29. Mena 1966 {published data only} Mena A, Grayson H, Cohen S. A study of thioridazine and its side-chain derivative, mesoridazine, in chronic male hospitalized psychiatric patients. Journal of New Drugs 1966;6(6):345-8.
30. Miyakawa 1973 {published data only} Miyakawa K, Mori H, Arai M, Yamauchi N, Hasue I, Mori H, Oana Y, Kamiya T, Shinozaki M, Satoh Y. Double blind controlled study of mesoridazine and thioridazine on schizophrenic inpatients. Clinical Evaluation 1973;1(2,3):181-212.
31. Montgomery 1992 {published data only} Montgomery SA, Green M, Rimon R, Heikkila L, Forsstrom R, Hirsch SR, Hallstrom C, Hippius H, Naber R, Khan MC, Sitsen JMA. Inadequate treatment response to des-enkephalin-gamma- endorphin compared with thioridazine and placebo in schizophrenia. Acta Psychiatrica Scandinavica 1992;86(2):97-103.
32. NIMH 1964 {published data only} Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Archives of general psychiatry 1964;10:246-61.
33. Nishikawa 1985 {published data only} Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry 1985;20:1161-6.
34. Phanjoo 1990 {published data only} Phanjoo-AL, Link-C. Remoxipride versus thioridazine in elderly psychotic patients. Acta Psychiatrica Scandinavica Supplementum 1990;358:181-5.
35. Pi 1990 {published data only} Pi E, Sramek J, Johnson T, Herrera J, Heh C, Costa J, Cutler N, Anath J. Subjective neuroleptic response and treatment outcome under open and double blind conditions - a preliminary report. Progressive Neuro-Psychopharmacology and Biological Psychiatry 1990;14:971-5.
36. Rada 1972 {published data only} Rada. Piperacetazine vs. thioridazine. Early Clinical Drug Evaluation Unit Reports 1972. [MEDLINE: 97344288].
37. Rada RT, Donlon PT. Piperacetazine vs. thioridazine for the control of schizophrenia in outpatients. Psychosomatics 1972;13(6):373-6.
38. Rasmussen1976 {published data only} Rasmussen K, Kirk I, Fairby A. Deposits in the lens and cornea of the eye during long termchlorpromazinemedication. Acta Psyciatrica Scandinavica 1976;53:1-6.
39. Realmuto 1982 {published data only} Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. American Journal of Psychiatry 1984;141(3):440-2.
40. Schiele 1961 {published data only} Schiele BC, Vestre ND, Stein KE. A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology 1961;22(3):151-62. [MEDLINE: 14498342].
41. Somerville 1960 {published data only} Somerville DM, Cohen PH, Graves GD. Phenothiazine side-effects. Comparison of two major tranquillizers. British Journal of Psychiatry 1960;106:1417-24.
42. Stabenau 1964 {published data only} Stabenau JR, Grinols DR. A double-blind comparison of thioridazine and chlorpromazine. Psychiatric Quarterly 1964;38(1):42-63.
43. Van Wyk 1971 {published data only} Van Wyk AJ, Marais GF. Chlorpromazine, clotiapine and thioridazine - a comparative clinical trial on Bantu psychotic patients. South African Medical Journal 1971;45(34):945-7.
44. Vestre 1970 {published data only} Vestre ND, Schiele BC. Differential drug effects of two phenothiazines (a controlled comparison of thioridazine and trifluoperazine in chronic schizophrenics). Diseases of the Nervous System 1970;31(12):821-5.
45. Weston 1973 {published data only} Weston MJ, Bentley R, Unwin A, Morris M, Harper MA. A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australia and New Zealand Journal of Psychiatry 1973;7(1):52-7.
46. Wolpert 1968 {published data only} Wolpert A, Sheppard C, Merlis S. Thiothixene, thioridazine, and placebo in male chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1968;9(4):456-64.
47. Zhang 1999 {published data only} Zhang NaiXuan, Wang TianHua, Zhong TianYong. Efficacy comparison of Thioridazine and chlorpromazine treating type I schizophrenia. Journal of Guangdon Medical College 1999;17(2):122-26.
48. Acker 1965 Acker CW. An exploration of the autonomic effects of phenothiazines. Psychopharmacologia 1965;7(2 (Feb 15)):150-8.
49. Altman 1973 Altman H, Mehta D, Evenson RC, Sletten IW. Behavioral effects of drug therapy on psychogeriatric inpatients. I. Chlorpromazine and thioridazine. Journal of the American Geriatric Society 1973;21(6):241-8.
50. Askar 1970 Askar A, Rakhawy Y, El-Grindy T. Thioridazine in treatment of psychiatric patients. Acta Psychiatrica Scandinavica Supplementum 1970;211:91. [MEDLINE: 4869441].
51. Bandelow 1992 Bandelow B, Muller P, Frick U, Gaebel W, Linden M, Muller Spahn F, Pietzcker A, Tegeler J. Depressive syndromes in schizophrenic patients under neuroleptic therapy. European Archives of Psychiatry and Clinical Neuroscience 1992;241(5):291-5.
52. Barker 1969 Barker JC, Miller M. A double blind comparative trial of pericyazine and thioridazine in chronic schizophrenia. British Journal of Psychiatry 1969;115(519):169-72.
53. Bigelow 1980 Bigelow LB, Weinberger DR, Wyatt RJ. Synergism of combined lithium-neuroleptic therapy: a double blind, placebo controlled case study. American Journal of Psychiatry 1981;138(1):81-3.
54. Bishop 1965 Bishop MP, Gallant DM, Sykes TF. Extrapyramidal side effects and therapeutic response. Archives of General Psychiatry 1965;13:155-62.
55. Blum 1969 Blum RA, Livingston PB, Shader RI. Changes in cognition, attention and language in acute schizophrenia. Diseases of the Nervous System 1969;30(1):31-6.
56. Branchey 1978 Branchey MH, Lee JH, Amin R, Simpson GM. High- and low-potency neuroleptics in elderly psychiatric patients. JAMA 1978 May 5;239:1860-2.
57. Caffey 1963 Caffey EM, Forrest IS, Frank TV, Klett CJ. Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry 1963;120:578-82.
58. Carpenter 1990 Carpenter W, Hanlon T, Heinrichs D, Summerfelt A, Kirkpatrick B, Levine J, Buchanan R. Continuous versus targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry 1990;147:9.
59. Claghorn 1972 Claghorn JL. A double-blind comparison of haloperidol (Haldol) and thioridazine (Mellaril) in outpatient children. Current Therapeutic Research 1972;14(12):785-9.
60. Claveria 1975 Claveria LE, Teychenne PF, Calne-DB, Haskayne L, Petrie A, Pallis CA, Lodge Patch IC. Tardive dyskinesia treated with pimozide. Journal of Neurological Science 1975 Apr;24(4):393-401.
61. Cottereau 1979 Cottereau M, Porier M, Loo H, Deniker P. no English title available [Le succinate de loxapine: un noveau neuroleptique]. L' Encephale 1979;5:251-67.
62. Cowley 1979 Cowley LM, Glen RS. Double-blind study of thioridazine and haloperidol in geriatric patients with a psychosis associated with organic brain syndrome. Journal of Clinical Psychiatry 1979;40(10):411-9.
63. Crowley 1981 Crowley TJ, Hydinger Macdonald M. Motility, Parkinsonism, and prolactin with thiothixene and thioridazine. Archives of General Psychiatry 1981 June;38:668-75.
64. Deutsch 1971 Deutsch M, Ananth JV, Ban TA. A clinical study with propericiazine in chronic psychotic patients. Current Therapeutic Research Clinical and Experimental 1971;13(6):353-8.
65. Dillenkofer 1974 Dillenkoffer RL, George RB, Bishop-MP, Gallant-DM. Electrocardiographic evaluation of thiothixene: a double-blind comparison with thioridazine. Advances in Biochemistry and Psychopharmacology 1974;9:487-95.
66. Downing 1963 Downing RW, Ebert JN, Shubrooks SJ. Effect of phenothiazines on the thinking of acute schizophrenics. Perceptual and Motor Skills 1963;17(2):511-20.
67. Dubin 1985 Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani Petrone C. Rapid tranquillization: the efficacy of oral concentrate. Journal of Clinical Psychiatry 1985;46(11):475-8.
68. Eccleston 1985 Eccleston D, Fairbairn AF, Hassanyeh F, McClelland HA, Stephens DA. The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. British Journal of Psychiatry 1985;147:623-30.
69. Eitan 1992 Eitan N, Levin Y, Ben Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85(1):74-6.
70. Essock 1996 Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacology Bulletin 1996;32(4):683-97.
71. Fragoso Mendes 1965 Fragoso Mendes, JM, Nunes Ferreira CN. Clinical trial with TPN12 (thioridazine metabolite) in the treatment of schizophrenia [Ensaio clinico com o TPN 12 (metabolito da tioridazina) no tratamento da esquizofrenia]. Actas Luso Esp Neurol Psiquiatr 1965;3:139-60.
72. Friedman 1961 Friedman DX, De Jong J. Treshold for drug induced akathisia. American Journal of Psychiatry 1964;vol unknown:930.
73. Gallant 1963 Gallant DM, Bishop MP, Timmons E, Steele CA. A controlled evaluation of trifluperidol: a new potent psychopharmacologic agent. Current Therapeutic Research 1963;5(9):463-71.
74. Gallant 1966 Gallant DM, Bishop MP, Timmons E, Gould AR. Thiothixene (P-4657B): a controlled evaluation in chronic schizophrenic patients. Current Therapeutic Research 1966 Apr;8:153-8.
75. Gardos 1974 Gardos G. Are antipsychotic drugs interchangeable?. Journal of Nervous and Mental Diseases 1974;159(5):343-8.
76. Geogotas 1981 Georgotas A, Gerbino L, Jordan B, McCarthy M, Gershon S, Kleinberg D, Lautin A, Stanley M, Rotrosen J. A double blind comparison of trebenzomine and thioridazine in the treatment of schizophrenia. Psychopharmacology 1981 May;73:292-4.
77. Gerlach 1977 Gerlach J, Rasmussen PT, Hansen L, Kristjansen P. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. Acta Psychiatrica Scandinavica 1977;55(4):251-60.
78. Gillis 1977 Gillis JS. The effects of selected antipsychotic drugs of human judgement. Current Therapeutic Research Clinical and Experimental 1977;21:224-32.
79. Goldberg 1965 Goldberg SC, Klerman GL, Cole JO. Changes in schizophrenia psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry 1965 Feb;111:120-33.
80. Goldberg 1967 Goldberg SC, Mattsson N, Cole JO, Klerman GL. Prediction of improvement in schizophrenia under four phenothiazines. Archives of General Psychiatry 1967;16:107-17.
81. Goldstein 1969 Goldstein MJ, Judd LL, Rodnick EH, LaPolla A. Psychophysiological and behavioral effects of phenothiazine administration in acute schizophrenics as a function of premorbid status. Journal of Psychiatric Research 1969;6(4):271-87.
82. Gonier 1970 Gonier T, Schiele BC, Vestre-ND. A comparison of haloperidol and thioridazine HC1 in chronic treatment-resistant schizophrenics. Behavioral Neuropsychiatry 1970 Jun-Jul;2(3):47-9.
83. Gottschalk 1975 Gottschalk L A, Biener R, Noble EP, Birch H, Wilbert DE, Heiser JF. Thioridazine plasma levels and clinical response. Comprehensive Psychiatry 1975;4:323-37.
84. Guo 1988 Guo GY. A double-blind controlled study of the efficacy and side effects of thioridazine and chlorpromazine in schizophrenia. Chung Hua Shen Ching Ching Shen Ko Tsa Chih Chinese Journal of Neurology and Psychiatry 1988 October;21:300-2, 319-20.
85. Hanlon 1965 Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA. The comparative effectiveness of eight phenothiazines. Psychopharmacologia 1965 Feb 15;7(2):89-106.
86. Hanlon 1975 Hanlon TE, Blatchley RJ, Kurland AA. Effects of control techniques on therapeutic outcome in a controlled clinical trial. International Pharmacopsychiatry 1975;10(3):169-76.
87. Hardeman 1970 Hardeman WJ, Bakker SJ. Double blind comparative study of the effects of thiothixene and thioridazine in twenty chronic schizophrenic patients. Psychiatria Neurologia Neurochirurgia 1970 Jan-Feb;73(1):1-7.
88. Harris 1992 Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran Johnson TK, Jeste DV. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacology Bulletin 1992;28(1):87-92. [MEDLINE: 1609047].
89. Holden 1968 Holden JM, Itil TM, Keskiner A, Fink M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Comprehensive Psychiatry 1968;9(6):633-43. [MEDLINE: 69083865].
90. Holden 1969 Holden JM, Itil TM. Laboratory changes with chlordiazepoxide and thioridazine, alone and combined. Canadian Psychiatric Association Journal 1969;14(3):299-301.
91. Hollister 1974 Hollister LE, Overall JE, Kimbell I Jr, Pokorny A. Specific indications for different classes of phenothiazines. Archives of General Psychiatry 1974;30(1):94-9.
92. Judd 1973 Judd LL, Goldstein MJ, Rodnick EH, Jackson NL Jr. Phenothiazine effects in good premorbid schizophrenics divided into paranoid-non-paranoid status. Archives of General Psychiatry 1973;29:207-21.
93. Jus 1974 Jus A, Pineau R, Jus K, Villeneuve A, Gautier J, Pires-P, Drolet A, Cote M, Villeneuve R. Penfluridol: a long-acting oral neuroleptic as therapeutic agent in chronic schizophrenia. Current Therapeutic Research Clinical and Experimental 1974;16(10):1041-58.
94. Klerman 1970 Klerman GL, Goldberg SG, Davis D. Relationship between the hospital milieu and the response to phenothiazines in the treatment of schizophrenics. Acta Psychiatrica Belgica 1970 Nov;70:716-29.
95. Kulkarni 1996 Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogens in acutely psychotic women. Schizophrenia Research 1996;20:247-52.
96. Lambert 1982 Lambert PA, Chabannes JP, Tell GP, Schechter PJ, Koch-Weser J. no english title available [Essai therapeutique du vinyl GABA , un inhibiteur de la GABA-transanimase, dans les dyskinesies tardives induites par les neuroleptiques]. L'Encephale 1982;VII:371-6.
97. Lapolla 1969 Lapolla. Acetophenazine versus thioridazine in the elderly. Psychopharmacology Bulletin 1969;6(3):101-3.
98. Linn 1979 Linn MW, Caffey EM Jr, Klett CJ, Hogarty GE, Lamb-HR. Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. A Veterans Administration cooperative study. Archives of General Psychiatry 1979 Sep;36(10):1055-66.
99. Lonowski 1978 Lonowski DJ, Sterling FE, Kennedy JC. Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study. Acta Psychiatrica Scandinavica 1978 Feb;57(2):97-102.
100. Mahmoud 2004 Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. Clinical Drug Investigation 2004;24(5): 275-86.
101. McCarthy 1986 McCarthy ST, John SM, McCarthy GL, Wollner L. The influence of chlormethiazole in comparison to thioridazine on body temperature and postural hypotension in healthy adults and healthy elderly volunteers. Acta Psychiatrica Scandinavica Supplementum 1986;329:40-4.
102. McClelland 1974 McClelland HA, Blessed G, Bhate S, Ali N, Clarke PA. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. British Journal of Psychiatry 1974;124(579):151-9.
103. Mellinger 1965 Mellinger TJ. Serum concentrations of thioridazine after different oral medication forms. American Journal of Psychiatry 1965;122:1119-22.
104. Melnyk 1966 Melnyk WT, Worthington AG, Laverty SG. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients. Canadian Psychiatric Association Journal 1966;11(5):410-3.
105. Meltzer 1969 Meltzer H, Shader R, Grinspoon L. The behavioral effects of Nicotinamine Adenine Dinucleotide in chronic schizophrenia. Psychopharmacologia 1969;15:144-52.
106. Menolascino 1985 Menolascino FJ, Ruedrich SL, Golden CJ, Wilson TE. Diagnosis and pharmacotherapy of schizophrenia in the retarded. Psychopharmacology Bulletin 1985;21(2):316-22.
107. Montero 1971 Montero E. Thioridazine compared with a combination of chlorpromazine and trifluoperazine hydrochloride in schizophrenic patients. 5th World Congress of Psychiatry, Ciudad de Mexico. November 28 - December 4, 1971:878.
108. Nelson 1975 Nelson AA Jr, Gold BH, Hutchinson RA, Benezra E. Drug default among schizophrenic patients. American Journal of Hospital Pharmacology 1975 Dec;32(12):1237-42.
109. Nordstrom 1996 Nordström A, Nyberg S, Farde L. Dopamine and serotonin receptor occupancy in patients treated with antipsychotics. 8th Congress of the Association of European Psychiatrists, London, UK. 1996.
110. Overall 1964 Overall JE, Hollister LE, Meyer F, Kimbell I, Shelton J. Imipramine and thioridazine in depressed and schizophrenic patients. Are there specific antidepressant drugs?. Journal of the American Medical Association 1964 Aug;189:605-8.
111. Payne 1974 Payne RW. Phenothiazine and Schizophrenic Thought Disorder. Unknown source 1974;10:69.
112. Peselow 1989 Peselow ED, Irons S, Rotrosen J, Teresa Alonso M, Dorsey F. GMI as a potential treatment in tardive dyskinisia. Psychopharmacology Bulletin 1989;25(2):277-80.
113. Prien 1973 Prien RF, Gillis RD, Caffey EM Jr. Intermittent pharmacotherapy in chronic schizophrenia. Hospital and Community Psychiatry 1973 May;24(5):317-22.
114. Rainaut 1975 Rainaut J. Statistical analysis of the activity of loxapine and thioridazine in a double-blind study [Analyse statistique de l'etude comparative double insu de l'activite de la loxapine et de la thioridazine]. Encephale 1975;1(2):147-60.
115. Rasmussen 1976 Rasmussen K, Kirk L, Faurbye A. Deposits in the lens and cornea of the eye during long-term chlorpromazine medication. Acta Psychiatrica Scandinavica 1976 Jan;53:1-6.
116. Reiter 1971 Reiter L, Hofmann G. [Differenzierte Indikationsstellung bei akuten psychotischen Zustõnden und Exazerbationen anhand einer kontrollierten Vergleichsstudie mit TPS 23 (Mesoridazin)]. V World Congress of Psychiatry, Ciudad de Mexico 28 N. 1971.
117. Remr 1974 Remr J, Nekolova J, Heinzl Z. A comparison of the therapeutic effect of oxypertine and thioridazine in chronic schizophrenia (a controlled trial). Activitas Nervosa Superior 1974;4:261-2.
118. Remr 1975 Remr J, Nekolova J, Heinzl Z. Comparison of the effect of oxypertine and thioridazine on sensorimotor activity in chronic schizophrenics: a controlled study. Activitas Nervosa Superior 1975;17(4):213-4.
119. Sandison 1960 Sandison RA, Whitelaw E, Currie JDC. Clinical trials with Melleril (TP21) in the treatment of schizophrenia. A two-year study. British Journal of Psychiatry 1960 Apr;106:732-41.
120. Schrodt 1982 Schrodt Jr GR, Wright JH, Simpson R, Moore DP, Sheldon C. Treatment of tardive dyskinesia with propranolol. Journal of Clinical Psychiatry 1982;43(8I):328-31.
121. Shavartsburd 1984 Shavartsburd A, Sajadi C, Morton V, Mirabi M, Gordon J, Smith RC. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology 1984 Aug;4(4):194-8.
122. Smith 1974 Smith GR, Taylor CW, Linkous P. Haloperidol versus thioridazine for the treatment of psychogeriatric patients: a double-blind clinical trial. Psychosomatics 1974;15(3):134-8.
123. Smith 1987 Smith RC, Baumgartner R, Ravichandran GK, Largen J, Calderon M, Burd A, Mauldin M. Cortical atrophy and white matter density in the brains of schizophrenics and clinical response to neuroleptics. Acta Psychiatrica Scandinavica 1987 Jan;75:11-9.
124. Smythies 1974 Smythies JR, Beaton JM. A pilot study of pimozide in schizophrenia. Journal of Psychiatric Research 1974;11:71-2.
125. Stucke 1969 Stucke W. Report on clinical trials of a new neuroleptic drug [Klinischer Erfahrungsbericht uber ein neues Neuroleptikum]. Medizinische Welt 1969 Feb;7:356-9.
126. Tetreault 1969 Tetreault L. Comparative study of 2 drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques 1969;22:1-8.
127. Ucer 1969 Ucer E, Kreger KC. A double-blind study comparing haloperidol with thioridazine in emotionally disturbed, mentally retarded children. Current Therapeutic Research Clinical and Experimental 1969 May;11:278-83.
128. Vaisanen 1981 Vaisanen K, Viukari M, Rimon R, Raisanen P. Haloperidol, thioridazine and placebo inmentally subnormal patients - serumlevels and clinical effects. Acta Psychiatrica Scandinavica 1981 Mar;63:262-71.
129. Van Wyck 1971 Van Wyk AJ, Marais GF. Chlorpromazine, clotiapine and thioridazine - a comparative clinical trial on Bantu psychotic patients. South African Medical Journal 1971 Aug 28;45(34):945-7.
130. Versiani 1968 Versiani M, da Silva JAR, Mundim FD. Loxapine versus thioridazine in the treatment of organic psychosis. Journal of Internal Medical Research 1980;8:22.
131. Vital-Herne 1976 Vital-Herne J, Gerbino L, Kay R, Katz IR, Opler LA. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics. Journal of Clinical Psychiatry 1986 Jul;47(7):375-9.
132. Walinder 1976 Walinder J, Skot A, Carlsson A, Roos BE. Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique. Archives of General Psychiatry 1976 Apr;33(4):501-5.
133. Wittenborn 1975 Wittenborn JR, Kiremitci N. A comparison of antidepressant medications in neurotic and psychotic patients. Archives of General Psychiatry 1975 Sep;32(9):1172-6.
134. Youssef 1991 Youssef HA. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Clinical Neuropharmacology 1991;14:16-21; discussion S22-3.
135. Tanimukai 1973 Tanimukai H, Inui M, Takahashi H, Kaneko Z. A double blind comparison of sulpiride with thioridazine on schizophrenia. Seishin Igaku (Clinical Psychiatry) 1973;15(2):197-207. [MEDLINE: 97353440].
136. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. British Medical Journal 1996;313:1200.
137. Annane 1996 Annane D, Girard F, Fabre JE, Raphael JC, Gajdos P. Near fatal case of self-poisoning with thioridazine. Intensive Care Medicine 1996 Dec; 22(12):1463-4.
138. Assie 1993 Assie MB, Sleight AJ, Koek W Eur J. Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Pharmacology 1993;237(2-3 (Jun 24)):183-9.
139. Bain 1998 Bain TA, Healy D, Shorter E (eds). The rise of psychopharmacology and the story of CINP. Budapest: Animula Publishing House, 1998.
140. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276(8):637-9.
141. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
142. BNF 1998 British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary Number 35. The Pharmaceutical Press, 1998.
143. Borison 1983 Borison RL, Diamond BI. Regional selectivity of neuroleptic drugs: an argument for site specificity. Brain Research Bulletin 1983 Aug;11(2):215-8.
144. Bowers 1975 Bowers MB. Thioridazine: central dopamine turnover and clinical effects of antipsychotic drugs. Journal of Clinical Pharmacolgy and Therapeutics 1975;17(1):73-8.
145. Buckley 1995 Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. Journal of Toxicology - Clinical Toxicology 1995;33(3):199-204.
146. Caldwell 1992 Caldwell CB, Gottesman II. Schizophrenia - a high-risk factor for suicide: clues to risk reduction. Suicide and Life-Threatening Behavior 1992;22:479-93.
147. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
148. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
149. Drolet 1999 Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. Journal of Pharmacology and Experimental Therapeutics 1999 Mar;288(3):1261-8.
150. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
151. Endicott 1976 Endicott J, Spitzer RL, Fleiss JL. The Global Assessment Scale. Archives of General Psychiatry 1976;33:766-71.
152. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
153. Guy 1976 Guy W. ECDEU Assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW publication No (ADM), 1976:124-585.
154. Heiman 1977 Heiman EM. Cardiac toxicity with thioridazine- tricyclic antidepressant combination. Journal Of Nervous And Mental Disease 1977 Aug; 165(2):139-43.
155. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
156. Higgins 2005 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2005, issue Issue 3.
157. Hollister 1995 Hollister LE. Electrocardiographic screening in psychiatric patients. The Journal of Clinical Psychiatry 1995 Jan;56(1):26-9.
158. Honingfeld 1965 Honingfeld G, Klett CJ. The Nurses Observation Scale for Inpatient Evaluation (NOSIE): a new scale for measuring improvement in chronic schizophrenia. Journal of Clinical Psychology 1965;21:65-71.
159. Jadad 1996 Jadad A, Moore A, Carrol D, Jenkinson C, Reynolds DJM, Gavanagh DJ, Mc Quay HJ. Assessing the quality of reports of randomised controlled trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
160. Jusic 1994 Jusic N, Lader M. Post-mortem antipsychotic drug concentrations and unexplained deaths. British Journal of Psychiatry 1994;165:787-91.
161. King 1995 King DJ. Neuroleptics and schizophrenia. Seminars in clinical psychopharmacology. Gaskell 1995:259-327.
162. Lipscomb 1980 Lipscomb PA. Cardiovascular side effects of phenothiazines and tricyclic antidepressants. A review with precautionary measures. Postgraduate Medicine 1980;67(3):189-92, 195-6.
163. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
164. Mehtonen 1991 Mehtonen OP, Aranko K, Malkonen L. A study of sudden death associated with the use of antipsychotic or antidepressant drugs. Acta Psychiatrica Scandinavica 1991;84:58-64.
165. MHRA Medicines and Healthcare products Regulatory Agency. http://www.mhra.gov.uk.
166. Moreau 1986 Moreau A, Jones BD, Banno V. Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia. Canadian Journal of Psychiatry 1986;31(4 (May)):339-41.
167. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
168. Psychotropics 2006 Psychotropics. http://www.psychotropics.dk/.
169. Rennie 1993 Rennie IG. Clinically important ocular reactions to systemic drug therapy. Drug Safety 1993;9(3):196-211.
170. Roden 1993 Roden DM. Torsade de pointes. Clinical Cardiology 1993;16(9):683-6.
171. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
172. Sedvall 1995 Sedvall G, Pauli S, Farde L, Karlsson P, Nyberg S, Nordstrom AL. Recent developments in PET scan imaging of neuroreceptors in schizophrenia. Israel Journal of Psychiatry and Related Sciences 1995;32(1):22-9.
173. Seeman 1983 Seeman P, Ulpian C. Neuroleptics have identical potencies in human brain limbic and putamen regions. European Journal of Pharmacology 1983;94(1-2):145-8.
174. Stuck 1998 Stuck AE, Rubenstein LZ, Wieland D, Vandenbroucke JP, Irwig L, Macaskill P, et al.Bias in meta-analysis detected by a simple, graphical test. BMJ 1998;316:469.
175. Thornley 1998 Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 1998;317:1181-84.
176. Thornley 2003 Thornley B, Rathbone J, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia (Cochrane Review). CochraneDatabase of Systematic Reviews 2003, Issue 2.Art. No.: CD000284. DOI: 10.1002/14651858.CD000284.pub2.
177. Trevitt 1998 Trevitt J, Atherton A, Aberman J, Salamone JD. Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology (Berl) 1998;137(1):61-6.
178. Turner 1990 Turner WM, Tsuang MT. The impact of substance abuse on the course and outcome of schizophrenia. Schizophrenia Bulletin 1990;16:18.
179. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
180. Sultana 2000 A Sultana, J Reilly, M Fenton. Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 2.Art. No.: CD001944. DOI:10.1002/14651858.CD001944.pub2.